Separation and characterization of clindamycin and related impurities in bulk drug by high-performance liquid chromatography-electrospray tandem mass spectrometry

Photodegradation of clindamycin by the dissolved black carbon is simultaneously regulated by ROS generation and the binding effect

As an essential source of the natural dissolved organic matter (DOM), dissolved black carbon (DBC) plays a vital role in the photodegradation of organics; however, there is rare information about the DBC-induced photodegradation mechanism of clindamycin (CLM), one of the widely used antibiotics. Herein, we discovered DBC-generated reactive oxygen species (ROS) stimulated CLM photodegradation. Hydroxy radical (•OH) could directly attack CLM by OH-addition reaction, the singlet oxygen (¹O₂) and superoxide (O₂^•-) contributed to the CLM degradation by transforming to •OH. In addition, the binding between CLM and DBCs inhibited the photodegradation of CLM by decreasing the concentration of freely dissolved CLM. Binding process inhibited CLM photodegradation by 0.25-1.98% at pH 7.0 and 6.1-41.77% at pH 8.5. These findings suggest that the photodegradation of CLM by DBC is simultaneously regulated by the ROS production and binding effect between CLM and DBC, benefiting the exact evaluation of the environmental impact of DBCs.

Isolation and identification of two unknown impurities from the raw material of clindamycin hydrochloride

Clindamycin hydrochloride belongs to the antibiotic family of lincomycin. It has the same antibacterial spectrum as lincomycin, but the antibacterial activity is four to eight times stronger than that of lincomycin. There have been some adverse reactions in clinical use of clindamycin hydrochloride and its finished drug products. The impurities in drugs are directly related to their safety. In this study, two unknown impurities were isolated from the raw material of clindamycin hydrochloride through various chromatographic methods. Their structures were identified as clindamycin isomer (impurity 1) and dehydroclindamycin (impurity 2) by mass spectrometry and NMR spectroscopy. Both of them were found for the first time. The two impurities exhibit a similar but lower antibacterial activity compared with clindamycin hydrochloride.

Separation and characterization of clindamycin phosphate and related impurities in injection by liquid chromatography/electrospray ionization mass spectrometry

A simple high-performance liquid chromatography/electrospray ionization tandem mass spectrometric (HPLC/ESI-MS/MS) method has been developed for the rapid identification of clindamycin phosphate and its degradation products or related impurities in clindamycin phosphate injection. Detection was performed by quadrupole time-of-flight mass spectrometry (Q-TOFMS) via an ESI source in positive mode. Clindamycin phosphate and its related substances lincomycin, 7-epilincomycin-2-phosphate, lincomycin-2-phosphate, clindamycin B, clindamycin B-2-phosphate, and clindamycin were identified simultaneously by HPLC/ESI-MS/MS results. Based on the MS/MS spectra of their quasi-molecular ions, the fragmentation pathways of clindamycin phosphate and its related substances were compared and proposed, which are specific and useful for the identification of the lincosamide antibiotics and related impurities. The method was rapid, sensitive and specific and can be used to identify clindamycin phosphate and its related impurities in clindamycin phosphate injection without control compounds.

Identification, isolation and characterization of impurities of clindamycin palmitate hydrochloride

Clindamycin palmitate hydrochloride is a water soluble hydrochloride salt of the ester of clindamycin and palmitic acid. It is inactive in vitro, rapid in vivo hydrolysis converts this compound to the antibacterially active clindamycin. Total 12 impurities at levels ranging from 0.05% to 0.5% were detected by isocratic reverse-phase high performance liquid chromatography (HPLC) using RI detector. The molecular weights of impurities were determined by LC-MS analysis. Two impurities were starting materials and the remaining impurities were isolated from crude samples/enriched mother liquors using reverse-phase preparative HPLC. Based on the spectral data the structures of these impurities were characterized as, clindamycin palmitate sulphoxides alpha-/beta-isomers (impurity I); clindamycin laurate (impurity II); lincomycin palmitate (impurity III); clindamycin myristate (impurity IV); epiclindamycin palmitate (impurity V); clindamycin palmitate 3-isomer (impurity VI); clindamycin pentadecanoate (impurity VII); clindamycin B-palmitate (impurity VIII); clindamycin heptadecanoate (impurity IX) and clindamycin stearate (impurity X). Structural elucidation of all impurities by spectral data ((1)H NMR, (13)C NMR, MS and IR) and formation of these impurities have been discussed in detail.